One of these suggested stocks features a dividend yield topping 10%.
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...